Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma

Journal of Clinical Oncology

Volumn 26, Issue 18, 2008, Pages 3105-3107

  Pantuck, Allan J ^a   Klatte, Tobias ^a   Seligson, David ^a   Atkins, Michael ^b   Belldegrun, Arie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CYTOKINE; INTERLEUKIN 2; SORAFENIB; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN; TUMOR MARKER;

CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DEATH; DRUG MEGADOSE; HUMAN; KIDNEY CARCINOMA; LETTER; LYMPH NODE METASTASIS; NEPHRECTOMY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME; ENZYMOLOGY; KIDNEY TUMOR; METABOLISM; NOTE; PREDICTION AND FORECASTING;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 46449100409     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.1935     Document Type: Letter

References (10)

1. Leibovich BC, Sheinin Y, Lohse CM, et al: Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 25:4757-4764, 2007
2. Bui MH, Seligson D, Han KR, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9:802-811, 2003
3. Sandlund J, Oosterwijk E, Grankvist K, et al: Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100:556-560, 2007
4. Atkins M, Regan M, McDermott D, et al: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714-3721, 2005
5. Klatte T, Zomorodian N, Kabbinavar FF, et al: Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma. J Clin Oncol 25:403s, 2007 (suppl; abstr 4601)
6. Jensen HK, Nordsmark M, Donskovl F, et al: CAIX and HIF-1a is metastatic clear cell carcinoma at baseline and during IL-2 therapy. First International CA-IX Symposium, Brussels, Belgium, November 14, 2007 (abstr)
7. Shah RB, Amin A, Braun T, et al: High Carbonic Anhydrase (CA) IX Protein Tissue Expression Predicts Response to Interleukin (IL)-2 based Therapy for Advanced Renal Cell Carcinoma Patients. J Urol 75:243 (suppl; abstr 725)
8. Patard JJ, Fergelot P, Karakiewicz PI, et al: Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer (in press)
9. Signoretti S, Atkins M: CAIX and the treatment of metastatic clear cell carcinoma. Presented at the First International CA-IX Symposium, Brussels, Belgium, November 14, 2007
10. Potter C, Harris AL: Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3:164-167, 2004